Synonyms	Tumor necrosis factor receptor superfamily member 17;B-cell maturation protein;CD269;TNFRSF17;BCM;BCMA
Species	Human
Expression_host	P.Pichia
Sequence	Met1-Ala54
Accession	Q02223
Mol_Mass	6.9 kDa
AP_Mol_Mass	12&15-28 kDa
Tag	C-His

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin level	< 1.0 EU per μg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Background

Tumor necrosis factor receptor superfamily; member 17 (TNFRSF17); also known as B cell maturation antigen (BCMA) or CD269 antigen; is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes; and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily; member 13b (TNFSF13BBAFF); and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members; and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-; TRAF6-; NIK-; and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Related Products

Proteins

Citations

Reviews/Q&A

Show all
Reviews
Q&A

... Show All Show Less

*Product Name:
*Catalog Number:
*Name:
*Email:
*Message:
*Country:
*When will you use it?	Within 1 month In 2 to 3 month In 4 to 6 month 6 months later
*Captcha:	Click to load Captcha